IP Verse

Anti Human Interleukin-1 Receptor Accessory Protein (Il1Rap) Antibodies And Uses Thereof

Patent No. EP3293202 (titled "Anti Human Interleukin-1 Receptor Accessory Protein (Il1Rap) Antibodies And Uses Thereof") was filed by Cantargia on Mar 5, 2015. The application was issued on Feb 7, 2024.

Patent Summary

Antibodies and antigen-binding fragments that specifically bind to interleukin-1 receptor accessory protein (IL1RAP) and inhibit binding of a reference antibody to IL1RAP. The antibodies can be used for diagnosing and treating diseases associated with IL1RAP expression, as well as for inhibiting interleukin-1 and IL33 signaling. The antibodies may be engineered for enhanced properties like longer half-life, altered effector functions, and low fucose glycosylation.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BLUEFIN BIOMEDICINE, INC.Nov 24, 2021DEHNS
ICHNOS SCIENCES SANov 24, 2021-
ZWICKER SCHNAPPAUF & PARTNERNov 24, 2021ZWICKER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3293202

CANTARGIA
Application Number
EP17185792A
Filing Date
Mar 5, 2015
Status
Patent Maintained As Amended
Jan 5, 2024
Publication Date
Feb 7, 2024
External Links
Slate, Register , Google Patents